References
1. Mohamed SY. Thalassemia Major: Transplantation or Transfusion and
Chelation. Hematology/Oncology and Stem Cell Therapy. 2017;10(4):290-8.
2. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M,
et al. Beta-Thalassemia Distribution in the Old World: an Ancient
Disease Seen from a Historical Standpoint. Mediterranean Journal of
Hematology and Infectious Diseases. 2017;9(e2017018).
3. Chamberlain CX, Zagadailov E, Kistler K, Colby JA, Ruiz K, editors.
Global Thalassemia Epidemiology: A Systematic Literature Review. 6th
European Hematology Association (EHA) Annual Congress; 2021 June 9-17.
4. Chong CC, Redzuan AM, Sathar J, Makmor-Bakry M. Patient Perspective
on Iron Chelation Therapy: Barriers and Facilitators of Medication
Adherence. Journal Patient Experience. 2021;8:2374373521996958.
5. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD,
et al. Consequences and Costs of Noncompliance with Iron Chelation
Therapy in Patients with Transfusion-Dependent Thalassemia: a Literature
Review. Transfusion. 2007;47(10):1919-29.
6. Reddy PS, Locke M, Badawy SM. A Systematic Review of Adherence to
Iron Chelation Therapy among Children and Adolescents with Thalassemia.
Annals of Medicine. 2022;54(1):326-42.
7. Arian M, Mirmohammadkhani M, Ghorbani R, Soleimani M. Health-Related
Quality of Life (HRQoL) in Beta-Thalassemia Major (beta-TM) Patients
assessed by 36-Item Short Form Health Survey (SF-36): a Meta-Analysis.
Quality of Life Research. 2019;28(2):321-34.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
et al. The PRISMA 2020 Statement: an Updated Guideline for Reporting
Systematic Reviews. BMJ. 2021;372:n71.
9. Raúl H, Álvarez-Pasquin MJ, Díaz C. Are Healthcare Workers’
Intentions to Vaccinate Related to Their Knowledge, Beliefs and
Attitudes? a Systematic Review. BMC Public Health. 2013;13:154.
10. Wang J, Zhu CK, Yu JQ, Tan R, Yang PL. Hypoglycemia and Mortality in
Sepsis Patients: A Systematic Review and Meta-analysis. Heart & Lung.
2021;50(6):933-40.
11. Al-Refaie FN, Wicken DG. Serum Non-transferrin-bound Iron in
Beta-Thalassaemia Major Patients Treated with Desferrioxamine and L1.
British Journal of Haematology. 1992(82):431-6.
12. Arboretti R, Tognoni G, Alberti D, Italian Colaborative Group on T.
Pharmacosurveillance and Quality of Care of Thalassaemic Patients.
European Journal of Clinical Pharmacology. 2001;56(12):915-22.
13. Kidson-Gerber GL, Francis S, Lindeman R. Management and Clinical
Outcomes of Transfusion-Dependent Thalassaemia Major in an Australian
Tertiary Referral Clinic. Medical Journal of Australia. 2008;188:72-5.
14. Lee W, Toh TH, Chai P, Soo T. Self-Reported Level of and Factors
Influencing The Compliance to Desferrioxamine Therapy in Multitransfused
Thalassaemias. Journal of Paediatrics and Child Health. 2011;47:535-40.
15. Haghpanah S, Nasirabadi S, Ghaffarpasand F, Karami R, Mahmoodi M,
Parand S, et al. Quality of Life among Iranian Patients with
Beta-Thalassemia Major Using the SF-36 Questionnaire. Sao Paulo Medical
Journal. 2013;131(3):166-72.
16. Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and
Satisfaction with Deferasirox (Exjade®) Compared with Deferoxamine in
Patients with Transfusion-Dependent Beta-Thalassemia. Hematology.
2014;19(4):187-91.
17. Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA,
et al. Quality of Life in Thalassemia: A Comparison of SF-36 Results
from the Thalassemia Longitudinal Cohort to Reported Literature and the
US Norms. American Journal of Hematology. 2011;86(1):92-5.
18. Bazi A, Sargazi-aval O, Safa A. Health-related Quality of Life and
Associated Factors Among Thalassemia Major Patients, Southeast of Iran.
Journal of Pediatric Hematology/Oncology. 2017;00:00.
19. Sobhani S, Rahmani F, Rahmani M, Askari M, Kompani F. Serum Ferritin
Levels and Irregular Use of Iron Chelators Predict Liver Iron Load in
Patients with Major Beta Thalassemia: a Cross-Sectional Study. Croatian
Medical Journal. 2019;60(5):405-13.
20. Yassouf MY, Alquobaili F, Kabalan Y, Mukhalalaty Y. Compliance with
Deferoxamine Therapy and Thyroid Dysfunction of Patients with
beta-Thalassemia Major in Syria. HEMOGLOBIN (International Journal for
Hemoglobin Research). 2019;43(3):218-21.
21. Sukhmani S, Shruti K, Priyanka D, Namita B, Praveen S. Adherence to
Iron Chelation Therapy and Its Determinants. International Journal of
Hematology-Oncology and Stem Cell Research. 2021;15(1).
22. Theppornpitak K, Trakarnsanga B, Lauhasurayotin S, Poparn H,
Chiengthong K, Sosothikul D, et al. A Study to Assess and Improve
Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia
Patients. Hemoglobin. 2021;45(3):171-4.
23. Mahmoud RA, Khodeary A, Farhan MS. Detection of Endocrine Disorders
in Young Children with Multi-Transfused Thalassemia Major. Italian
Journal of Pediatrics. 2021;47(1):165.
24. Chai ASC, Draman N, Mohd Yusoff SS, Azman NF, Zulkifli MM, Yaacob
NM, et al. Non-Compliance to Iron Chelation Therapy in Patients with
Transfusion-Dependent Thalassaemia. Pediatric Hematology Oncology
Journal. 2021;6(4):207-15.
25. Lam JCM, Lee SY, Koh PL, Fong SZ, Abdul-Kadir NI, Lim CY, et al.
Clinical and Health-Related Quality of Life Outcomes of
Transfusion-Dependent Thalassaemia Patients in Singapore. Blood Cells,
Molecules and Diseases. 2021;88:102547.
26. Badur A, Ozbalci D, Alanoglu E. Evaluation of the Relationship
between Sociodemographic Characteristics, Quality of Life, Depression,
Drug Compliance and Biochemical Parameters in Patients with Thalassemia
Major in Isparta. Annals of Medical Research. 2021;28(8).
27. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al.
Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients
with Thalassemia Major. The New England Journal of Medicine.
1985;312(25):1600-3.
28. Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt
E, et al. Prevention of Heart Disease by Subcutaneous Desferoxamine in
Patients with Thalassaemia Major. Australian and New Zealand Journal of
Medicine. 1993;23(6):656-61.
29. Mokhtar GM, Gadallah M, El Sherif NH, Ali HT. Morbidities and
Mortality in Transfusion-Dependent Beta-Thalassemia Patients
(Single-Center Experience). Pediatric Hematology and Oncology.
2013;30(2):93-103.
30. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy
and Safety of a Novel Combination of Two Oral Chelators
Deferasirox/Deferiprone over Deferoxamine/Deferiprone in Severely Iron
Overloaded Young Beta Thalassemia Major Patients. European Journal of
Haematology. 2015;95(5):411-20.
31. Angelucci E, Barosi GC, C. Italian Society of Hematology Practice
Guidelines for the Management of Iron Overload in Thalassaemia Major and
Related Disorders. Haematologica. 2008:93:5.
32. Mohd Ibrahim H, Afifah H, Elizabeth G. Clinical Practical Guidelines
Management of Transfusion Dependent Thalassaemia. Malaysia. 2009.
33. Walker JM. Thalassaemia Major and the Heart: a Toxic Cardiomyopathy
Tamed? Heart. 2013:827-34.
34. Al-Kloub MI, MA AB, Al Khawaldeh OA, Al Tawarah YM, Froelicher ES.
Predictors of Non-Adherence to Follow-Up Visits and Deferasirox
Chelation Therapy among Jordanian Adolescents with Thalassemia Major.
Pediatric Hematology and Oncology. 2014;31(7):624-37.
35. Richardson ME, Matthews RN, Alison JF, Menahem S. Prevention of
heart disease by subcutaneous desferrioxamine in patients with
thalassaernia major.